Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024, Highlighting AI-Driven Robotic Surgery Advancements

Monogram Technologies Receives Prestigious Industry Recognition

Monogram Technologies Inc. (NASDAQ: MGRM), an AI-driven robotics company focused on improving human health, has been named the Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook 1

1

2

2

. This prestigious award recognizes Monogram's stellar reputation and trust among customers and industry peers, as evidenced by numerous nominations from Medical Tech Outlook's subscribers.

Innovative mBôs TKA System at the Forefront

The award particularly highlights Monogram's mBôs TKA (Total Knee Arthroplasty) System, which represents a significant advancement in orthopedic joint replacement technology. The mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of FDA-cleared mPress press-fit implants 1

1

.

AI and Robotics Driving Orthopedic Innovation

Monogram Technologies is at the forefront of combining artificial intelligence with advanced robotics in the field of orthopedic surgery. The company's approach involves:

1. 3D printing technology
2. Advanced machine vision
3. AI algorithms
4. Next-generation robotics

This innovative combination aims to enable patient-optimized orthopedic implants at scale, potentially revolutionizing the standard of care in orthopedic medicine 2

2

.

Potential Benefits and Future Applications

The mBôs system, coupled with mVision navigation, is expected to offer several advantages:

• More personalized knee implants for patients
• Well-balanced, better-fitting knee replacements
• Bone-sparing implant procedures

Monogram anticipates that its technology may have applications beyond knee replacements, exploring other clinical and commercial uses for its navigated mBôs precision robot and mVision navigation 1

1

2

2

.

Regulatory Status and Future Outlook

While Monogram has obtained FDA clearance for its mPress implants, the company has applied for 510(k) clearance for its robotic products. The timing and ability to obtain such clearances remain uncertain, as stated in the company's forward-looking statements 1

1

2

2

.

Industry Impact and Recognition

Ben Sexson, CEO of Monogram Technologies, expressed gratitude for the award, stating, "This award further validates Monogram's confidence in our mBôs TKA System, in the potential advantages of our technology, and our focus on improving human health" 1

1

. The recognition by Medical Tech Outlook, following an exhaustive evaluation by industry experts, underscores the potential impact of Monogram's technology on the orthopedic surgery field.

As Monogram Technologies continues to develop its AI-driven robotic solutions, the orthopedic industry watches closely. The company's innovative approach could potentially lead to improved patient outcomes and set new standards in joint replacement procedures, marking a significant step forward in the integration of AI and robotics in healthcare.